XENON PHARMACEUTICALS INC. Total Assets
XENON PHARMACEUTICALS INC. (XENE) had Total Assets of $1.30 billion as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets
us-gaap:Assets · last filed 2026-08-06
- 2026-06-30: Assets $1.30B.
- 2026-03-31: Assets $1.39B.
- 2025-12-31: Assets $633.16M.
- 2025-09-30: Assets $607.84M.
| Period end | Assets |
|---|---|
| 2026-06-30 | $1.30B 10-Q · filed 2026-08-06 |
| 2026-03-31 | $1.39B 10-Q · filed 2026-05-07 |
| 2025-12-31 | $633.16M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $607.84M 10-Q · filed 2025-11-03 |
| 2025-06-30 | $674.28M 10-Q · filed 2025-08-11 |
| 2025-03-31 | $743.28M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $798.14M 10-K · filed 2026-02-26 |
| 2024-09-30 | $835.90M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $884.01M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $919.02M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $964.80M 10-K · filed 2025-02-27 |
| 2023-09-30 | $671.09M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $684.90M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $719.87M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $754.15M 10-K · filed 2024-02-29 |
| 2022-09-30 | $775.81M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $807.38M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $558.06M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $572.01M 10-K · filed 2023-03-01 |
| 2021-09-30 | $264.35M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $274.71M 10-Q · filed 2021-08-11 |
| 2021-03-31 | $290.67M 10-Q · filed 2021-05-11 |
| 2020-12-31 | $189.19M 10-K · filed 2022-03-01 |
| 2020-09-30 | $199.13M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $210.68M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $237.04M 10-Q/A · filed 2020-05-26 |
| 2019-12-31 | $147.70M 10-K · filed 2021-03-01 |
| 2019-09-30 | $98.90M 10-Q · filed 2019-11-05 |
| 2019-06-30 | $105.89M 10-Q · filed 2019-08-06 |
| 2019-03-31 | $114.55M 10-Q · filed 2019-05-07 |
| 2018-12-31 | $122.43M 10-K · filed 2020-03-09 |
| 2018-09-30 | $130.46M 10-Q · filed 2018-11-06 |
| 2018-06-30 | $65.44M 10-Q · filed 2018-08-07 |
| 2018-03-31 | $37.76M 10-Q · filed 2018-05-08 |
| 2017-12-31 | $46.12M 10-K · filed 2019-03-06 |
| 2017-09-30 | $46.36M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $54.23M 10-Q · filed 2017-08-03 |
| 2017-03-31 | $60.79M 10-Q · filed 2017-05-09 |
| 2016-12-31 | $67.49M 10-K · filed 2018-03-07 |
| 2016-09-30 | $73.37M 10-Q · filed 2016-11-03 |
| 2016-06-30 | $55.69M 10-Q · filed 2016-08-03 |
| 2016-03-31 | $61.15M 10-Q · filed 2016-05-10 |
| 2015-12-31 | $63.95M 10-K · filed 2017-03-08 |
| 2015-09-30 | $69.94M 10-Q · filed 2015-11-10 |
| 2015-06-30 | $76.53M 10-Q · filed 2015-08-13 |
| 2015-03-31 | $79.40M 10-Q/A · filed 2015-08-13 |
| 2014-12-31 | $87.42M 10-K · filed 2016-03-08 |
| 2014-09-30 | $54.14M 10-Q · filed 2014-12-15 |
| 2013-12-31 | $54.49M 10-K · filed 2015-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 |